Nature Communications (Jan 2020)
Single-cell analysis based dissection of clonality in myelofibrosis
- Elena Mylonas,
- Kenichi Yoshida,
- Mareike Frick,
- Kaja Hoyer,
- Friederike Christen,
- Jaspal Kaeda,
- Matthias Obenaus,
- Daniel Noerenberg,
- Cornelius Hennch,
- Willy Chan,
- Yotaro Ochi,
- Yuichi Shiraishi,
- Yusuke Shiozawa,
- Thorsten Zenz,
- Christopher C. Oakes,
- Birgit Sawitzki,
- Michaela Schwarz,
- Lars Bullinger,
- Philipp le Coutre,
- Matthew J. J. Rose-Zerilli,
- Seishi Ogawa,
- Frederik Damm
Affiliations
- Elena Mylonas
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Kenichi Yoshida
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Mareike Frick
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Kaja Hoyer
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Friederike Christen
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Jaspal Kaeda
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Matthias Obenaus
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Daniel Noerenberg
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Cornelius Hennch
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Willy Chan
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Yotaro Ochi
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Yuichi Shiraishi
- Laboratory of Sequence Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo
- Yusuke Shiozawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Thorsten Zenz
- Department of Medical Oncology and Hematology, University Hospital Zurich / University of Zurich
- Christopher C. Oakes
- Division of Hematology, Department of Internal Medicine, The Ohio State University
- Birgit Sawitzki
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute for Medical Immunology
- Michaela Schwarz
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Lars Bullinger
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Philipp le Coutre
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- Matthew J. J. Rose-Zerilli
- Cancer Sciences, Faculty of Medicine, University of Southampton
- Seishi Ogawa
- Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University
- Frederik Damm
- Charité—Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Hematology, Oncology, and Tumor Immunology
- DOI
- https://doi.org/10.1038/s41467-019-13892-x
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Myelofibrosis is a myeloproliferative neoplasm. Here, the authors show the clonal evolution of myelofibrosis during JAK inhibitor therapy, revealing how the treatment results in an increase in clonal complexity and a gain of RAS pathway mutations.
